Cumberland Pharmaceuticals INC Form 4 insider transactions

Cumberland Pharmaceuticals Director Caroline Young acquired 176 shares of common stock through a pre-arranged 10b5-1 trading plan in July 2025.

Cumberland Pharmaceuticals Director James Jones increased his direct ownership of common stock through a pre-arranged 10b5-1 trading plan in July 2025.

Cumberland Pharmaceuticals' Chairman and CEO, A.J. Kazimi, increased his direct ownership of common stock through a pre-arranged Rule 10b5-1 trading plan.

Cumberland Pharmaceuticals Director Kenneth Krogulski acquired additional common stock through a pre-arranged trading plan in July 2025.

A director at Cumberland Pharmaceuticals Inc. has acquired additional common stock through a pre-arranged trading plan, increasing their beneficial ownership.

A.J. Kazimi, Chairman and CEO of Cumberland Pharmaceuticals Inc., reported a series of small, pre-scheduled common stock acquisitions through a Rule 10b5-1 trading plan.

Cumberland Pharmaceuticals Inc. Director James Jones acquired additional common stock shares through a pre-arranged Rule 10b5-1 trading plan during June 2025.

A director at Cumberland Pharmaceuticals Inc. has increased their direct beneficial ownership of common stock through a series of pre-planned purchases executed under a Rule 10b5-1 trading plan.

Cumberland Pharmaceuticals Inc. Director Kenneth Krogulski has increased his direct beneficial ownership of common stock through a series of pre-scheduled purchases under a Rule 10b5-1 trading plan during May 2025.

Cumberland Pharmaceuticals Inc. Director James Jones acquired additional shares of common stock throughout May 2025 via a pre-arranged Rule 10b5-1 trading plan.

Cumberland Pharmaceuticals Inc. Director Caroline Young acquired 84 shares of common stock in May 2025 through a pre-arranged Rule 10b5-1 trading plan, increasing her direct beneficial ownership to 32,569 shares.

Cumberland Pharmaceuticals' Chairman and CEO, A.J. Kazimi, has increased his direct beneficial ownership in the company by acquiring 160 shares of common stock through a series of open market purchases in May 2025.

Director Caroline Young continues to increase her holdings in Cumberland Pharmaceuticals through a pre-arranged Rule 10b5-1 trading plan.

Director James Jones of Cumberland Pharmaceuticals incrementally increased his holdings of common stock through a pre-arranged 10b5-1 trading plan throughout April 2025.

A.J. Kazimi, Chairman and CEO of Cumberland Pharmaceuticals, reports a series of open market purchases of common stock executed under a pre-arranged 10b5-1 trading plan.

Director Kenneth Krogulski of Cumberland Pharmaceuticals incrementally increased his holdings of common stock through a pre-arranged 10b5-1 trading plan throughout April 2025.

Director Caroline Young of Cumberland Pharmaceuticals increased her holdings through a pre-arranged 10b5-1 trading plan, acquiring shares in multiple transactions between March 3, 2025, and March 31, 2025.

Director James Jones of Cumberland Pharmaceuticals incrementally increased his holdings of common stock through a pre-arranged 10b5-1 trading plan.

Cumberland Pharmaceuticals' Chairman and CEO, A.J. Kazimi, has been consistently purchasing small quantities of company stock through a pre-arranged 10b5-1 trading plan.

Director Kenneth Krogulski of Cumberland Pharmaceuticals increased his holdings of common stock through a series of purchases executed under a pre-arranged Rule 10b5-1 trading plan.

Caroline Young, a director at Cumberland Pharmaceuticals, acquired 1,000 shares of common stock on March 17, 2025.

Director Kenneth Krogulski reports acquisition of Cumberland Pharmaceuticals shares via restricted stock award.

Director James Jones of Cumberland Pharmaceuticals acquired 1,000 shares of common stock at $5.17 per share on March 17, 2025.

Joseph C. Galante, a director of Cumberland Pharmaceuticals, acquired 1,000 shares of common stock at $5.17 per share on March 17, 2025.

Martin S. Brown Jr., a director of Cumberland Pharmaceuticals, acquired 1,000 shares of common stock at $5.17 per share on March 17, 2025.

James L. Herman, VP and Chief Compliance Officer of Cumberland Pharmaceuticals, reports acquiring 2,500 options in the company's common stock.

Chris T. Bitterman, Vice President of Sales & Marketing at Cumberland Pharmaceuticals, reports changes in beneficial ownership, including the acquisition and disposal of derivative securities.

Todd M. Anthony, Vice President of Organizational Development at Cumberland Pharmaceuticals, reports the acquisition of options to purchase 3,000 shares of company stock.

A.J. Kazimi, CEO of Cumberland Pharmaceuticals, reports disposing of shares to cover tax obligations related to vesting shares and acquiring options.

John Hamm, CFO of Cumberland Pharmaceuticals, reports the withholding of shares to cover tax obligations related to vesting shares.